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abstract
Chronic	myelogenous	leukemia	(CML)	is	a	clonal	bone	marrow	stem	cell	disorder	associated	with	a	characteristic	chromosomal	
translocation	called	the	Philadelphia	chromosome	which	caused	a	proliferation	of	mature	granulocytes	(neutrophils,	eosinophils	and	
basophils)	and	their	precursors,	increasing	unregulated	growth	of	predominantly	myeloid	cells	in	the	bone	marrow	and	its	accumulation	
in	the	blood.	As	myeloproliferative	disease,	Chronic	Myelogenous	Leukemia	or	CML	is	a	malignancy	of	the	sixth-highest,	reaching	15%	
of	all	blood	malignancies	in	adults	with	an	incidence	of	1.1	per	100,000	population	(Ugroseno,	2012).	The	CML	diagnosis	is	made	based	
on	a	presence	of	Philadelphia	chromosome	due	to	the	existence	of	a	reciprocal	translocation	of	chromosomes	9	and	chromosome	22	
t	(9.22),	and	raises	the	fusion	of	Break	Cluster	Region	(BCR)	gene	of	chromosome	22	on	band	q11	by	Abelson	Murine	Leukemia	(ABL).	
The	fused	BCR-ABL	gene	has	BCR	sequences	of	different	length,	so	it	produces	a	protein	that	has	a	different	molecular	weight.	Despite	
having	different	length	of	BCR	sequences,	however,	the	length	of	fuses	ABL	gene	sequence	is	constant.	Associated	with	this	different	
BCR	sequence	length	are	the	three	variations	of	the	BCR-ABL	gene	fusion.	The	first	variation	is	a	Major	Break	Cluster	(M-BCR),	the	
BCR	gene	break	is	found	in	exon	2	in	e13-E14	region.	This	type	of	CML	is	the	fusion	of	BCR	exon	b2	or	b3	to	ABL	exon	a2,	forming	
two	major	transcripts	of	the	b2a2	or	b3a2,	which	has	a	protein	product	with	210	kD	weight	or	referred	to	as	p210.	The	second	variation	
is	Minor	BCR	(m-BCR),	which	has	e1a2	fusion.	CML	with	BCR-ABL	gene	fusion	of	this	type	has	a	protein	product	with	a	molecular	
weight	of	190	kDa	or	called	p190.	The	third	variation	is	micro-BCR	(m-BCR),	with	BCR	gene	break	between	exons	E19	and	e20b	that	
form	mRNA	transcripts	e19a2,	with	BCR-ABL	protein	P230.	This	fused	gene	can	be	detected	with	qualitative	multiplex	PCR.
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abstrak
Chronic	myelogenous	 leukemia	 (CML)	adalah	 kelainan	 klonal	 dari	 stemsel	 sumsum	 tulang	belakang	 terkait	 dengan	adanya	
translokasi	kromosom	t	(9,22)	atau	yang	lebih	dikenal	dengan	kromosom	philadelphia.	Translokasi	kromosom	t	(9,22)	menyebabkan	
terjadinya	proliferasi	dari	granulosit	dewasa	(neutrofils,	eosinofils	dan	basofil).	Proliferasi	sel	granulosit	ini	menyebabkan	terjadinya	
peningkatan	dari	pertumbuhan	yang	tidak	terkendali	pada	sel	mieloid	di	bone	marrow	dan	terakumulasi	dalam	darah.	Sebagai	suatu	
kelainan	 	myeloproliferatif,	Chronic	Myelogenous	Leukemia	atau	CML	merupakan	malignansi	urutan	ke	enam	terbesar,	di	mana	
kelainan	 ini	mencapai	angka	15%	dari	seluruh	malignansi	darah	pada	orang	dewasa	dengan	insidensi	1.1	per	100,000	populasi	
penduduk	(Ugroseno,	2012).	Diagnosis	CML	dibuat	berdasarkan	pada	adanya	kromosom	Philadelphia,	yang	terjadi	sebagai	akibat	
adanya	translokasi	resiprokal	antara	kromosom	9	dan	kromosom	22		atau	t	(9.22).	Translokasi	ini	menyebabkan	munculnya	fusi	gen	
BCR(Break	Cluster	Region)	pada		chromosome	22	lengan	q11	dengan	gen	Abl	atau	Abelson	Murine	Leukemia.	Fusi	gen	BCR-ABL	
memiliki	sekuen	gen	BCR	dengan	panjang	sekuen	yang	berbeda,	sehingga	menghasilkan	produk	protein	dengan	berat	molekul	yang	
berbeda.	Terkait	dengan	perbedaan	panjang	sekuen	gen	BCR,	menimbulkan	adanya	variasi	fusi	gen	BCR-ABL,	yakni	pertama	Major	
Break	Cluster	(M-BCR),	fusi	gen	BCR	ditemukan	pada	exon	2	di	daerah	e13-E14.	Tipe	ini	merupakan	fusi	gen	BCR	exon	b2	atau	b3	
dengan	gen	ABL	exon	a2,	membentuk	2	jenis	transkrip	utama,	yakni	b2a2	atau	b3a2,	di	mana	produk	proteinnya	memiliki	berat	210	
kD	atau	biasa	ditulis	dengan	p210.	Variaso	kedua	adalah		Minor	BCR	(m-BCR),	yang memiliki fusi pada titik e1a2. CML dengan fusi	 	 	 	 	 	 	 	 	
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gen	BCR-ABL		type	ini	memiliki	produk	protein	dengan	berat	molekul	190	kDa	atau	disebut	p190.	Variasi	ketiga	adalah	micro-BCR	
(m-BCR),	di	mana	gene	BCR	terletak	pada	exons	E19	dan	e20b	membentuk	transkrip	mRNA	e19a2,	dengan	produk	protein	p230.	
Keseluruhan	variasi	tersebut	dapat	dideteksi	dengan	qualitative	multiplex	PCR.
Kata	kunci:	CML,	Kromosom	Philadelphia,	translokasi	t(9,22),	fuse	gen	BCR	ABL,	PCR	Multipleks	kualitatif
In CML, the form of the BCR-ABL gene fusion will 
then be transcribed into Bcr-Abl fusion protein that has 
the ability to phosphorylate a substrate which further 
activates transduction cascade Ras-signaling pathways2. A 
tyrosine kinase is an enzyme that can transfer a phosphate 
group from ATP to a protein in a cell. The Ras pathway 
is a signaling center that forwards signals both upstream 
and downstream, with 3 signaling pathway downstream 
of Ras, namely Ras-Raf-MAP-kinase pathway, Akt/PKB 
pathway and RAL pathway. The substrate phosphorylation 
may activate Ras/Raf/MAPK/ERK JUN kinase, Myc, 
and JAK-STAT, and form PI3K (phosphatidylinositol-3 
kinase)-AKT protein, which plays a role in the inhibition 
of apoptosis, cell cycle progression, and DNA repair, thus 
resulted in the deregulation of cell proliferation, through 
increased leukocytes proliferation.3
CML	Diagnosis
CML diagnosis is made based on history, physical and 
laboratory examination, which includes a complete blood 
count, peripheral blood smear, cytogenetic examination to 
identify the presence of the Philadelphia chromosome or 
the inspection of Bcr-Abl gene fusion.4 Most of these are 
found adults. CML is rare in children.
Complete blood examination is intended to determine 
the amount of various kinds of cells in blood. In complete 
blood count examination, white blood cells often increase, 
typically > 25 109/L and could even above 100 ×109/L. 
Differential cell shows granulocytes in all stages of 
maturation, ranging from the blast to the mature form. 
Basophils also increases, but only at 10–15% of the patients 
who have basophils ? 7% in peripheral blood. Eosinophils 
also increases lightly. Platelets increases in 30–50% of the 
patients and only a few per cent were in excess of 1,000 × 
109/L.1,4
Cytogenetic examination of philadelphia chromosome 
or molecular examination of BCR-ABL gene fusion are 
performed to confirm the diagnosis. In some cases, about 
5% of Philadelphia chromosome cannot be detected, so 
that it requires other methods, such as fluorescent in situ 
hybridization (FISH) and molecular detection of BCR-ABL 
gene fusion by examination of Polymerase Chain Reaction 
(PCR) for establishing CML diagnosis.5
CML	examination	with	Polymerase	Chain	Reaction	(PCR)
PCR is an in vitro DNA amplification technique in 
specific regions bounded by two oligonucleotide primer. 
Primer is used as a barrier region is propagated single-
stranded DNA sequence with its complementary DNA 
template. The process is similar to the process of DNA 
replication in vivo, which is semi-conservative. PCR works 
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Chronic Myelogenous Leukemia or CML is a 
malignancy of the sixth-highest, reaching 15% of all 
blood malignancies in adults with an incidence of 1.1 
per 100,000 population1. Specific characteristics of CML 
is the presence of Philadelphia chromosome due to the 
existence of a reciprocal translocation of chromosomes 
9 and chromosome 22 t (9.22). The presence of the 
translocation t (9; 22) raises the fusion of Break Cluster 
Region (BCR) gene of chromosome 22 on band q11 by 
Abelson Murine Leukemia (ABL), which causes adult 
granulocytes proliferation grown without being interrupted 
by differentiation1. Chromosomal translocation, the gene 
ABL from chromosomes 9, which is replaced by the BCR 
gene on chromosome 22, is translated as Bcr-Abl fusion 
protein that has the ability to transform.
The fused BCR-ABL gene has BCR sequences of 
different length, so it produces a protein that has a different 
molecular weight. Despite having different length of BCR 
sequences, however, the length of fuses ABL gene sequence 
is constant. Associated with this different BCR sequence 
length are the three variations of the BCR-ABL gene fusion. 
The first variation is a Major Break Cluster (M-BCR), the 
BCR gene break is found in exon 2 in e13-E14 region. This 
type of CML is the fusion of BCR exon b2 or b3 to ABL 
exon a2, forming two major transcripts of the b2a2 or b3a2, 
which has a protein product with 210 kD weight or referred 
to as p210. The second variation is Minor BCR (m-BCR), 
which has e1a2 fusion. CML with BCR-ABL gene fusion 
of this type has a protein product with a molecular weight of 
190 kDa or called p190. The third variation is micro-BCR 
(m-BCR), with BCR gene break between exons E19 and 
e20b that form mRNA transcripts e19a2, with BCR-ABL 
protein P230. The transcript is even rarer, ie, with a clinical 
picture of netrophilia and or thrombocytosis.2
Figure	1. BCR-ABL gene fusion as a result of chromosomal 
translocation t (9,22) (Goh et	al., 2006)
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to help speed up the diagnosis of malignant diseases such 
as chronic leukemia with BCR-ABL gene fusion.1
Stages of BCR-ABL examination include RNA 
isolation of peripheral blood samples of CML patients 
using the High Pure RNA Isolation Kit, cDNA synthesis, 
using RNA that had been isolated, converted into cDNA 
using Transcriptor First Strand cDNA Synthesis Kit, and 
examination of the BCR-ABL gene fusion using multiplex 
PCR technique.
Multiplex	PCR	assay	 for	 the	detection	 of	BCR-ABL	gene	
fusion	
Multiplex-PCR is a modification of PCR reaction in 
order to be faster in detecting gene deletions or duplications. 
This process amplifies genomic DNA samples using 
multiple primers and a temperature-mediated DNA 
polymerase in a thermal cycler. Multiplex-PCR was first 
described in 1988 as a method to detect deletions in the 
dystrophin gene.5 It has also been used with the steroid 
sulfatase gene.6 In 2008, the multiplex-PCR was used for 
analysis of microsatellites and SNPs.7 Multiplex-PCR 
consists of multiple primer sets within a single PCR mixture 
to produce amplicons of varying sizes that are specific to 
different DNA sequences. By targeting multiple genes at 
once, additional information may be gained from a single 
test run that otherwise would require several times the 
reagents and more time to perform. Cross et	al, (1994) have 
used a multiplex-PCR for the identification of BCR-ABL 
transcripts simultaneously from two or more genes in the 
same reaction. The goal is to qualitatively detect the BCR-
ABL gene fusion. One example of the use of Multiplex PCR 
Examination is to identify for the presence of BCR-ABL 
gene fusion by using the following primers:
Sense primers A1: caacagtccttcgacagcag (5’–3‘) on bcr 
exon 1
B1: gctacggagaggctgaagaa (5’–3‘) on bcr exon 11
Anti-sense primer C1: cgtgatgtagttgcttggga (5’–3‘) on abl 
exon 3
Primer sequences in nested RT-PCR
Sense primers A2: caacagtccttcgacagcag (5’–3‘) on bcr 
exon 1
B2: gtgcagagtggagggagaac (5’–3‘) on bcr exon 12
Anti-sense primer C2: acaccattccccattgtgat (5’–3‘) on abl 
exon 3
The next phase is gel electrophoresis using 2% agarose. 
Results of electrophoresis was stained with ethidium 
bromide (by soaking for 15–20 minutes). PCR results is 
positive when 627 bands are obtained for b3a2 transcript 
(e13a2), 552 for the b2a2 (e14a2), 378 for b2a3, and 580 
for b1a1.8
Examination	of	response	to	therapy	using	RQ-PCR
Examination of response to therapy aims to quantitatively 
detect BCR-ABL fusion gene transcript derived from 
mRNA isolation of the patients’ blood samples, using Real 
Time PCR or better known as Quantitative-PCR atau Real 
Time Quantitative–PCR atau RQ PCR. Using RQ-PCR the 
quantity of PCR products generated from each amplification 
cycle is done by measuring the strength/increase in 
fluorescence generated by the fluorescent molecules used 
in the reaction.
RQ PCR products can be quantified relative to 
control genes or house keeping gene. In particular, 
quantification process relies on a standard curve obtained 
from known concentration of plasmid DNA. RQ-PCR 
has many advantages over conventional PCR. RQ-PCR 
allows amplification and detection process carried out 
simultaneously in one tube so that the process takes place 
more quickly and efficiently.
In CML treatment management, Real Time Quantitative 
PCR is used to evaluate molecular response of BCR-
ABL therapy, namely by calculating residual BCR-ABL 
transcripts within 2 weeks after reaching CcyR (Complete 
Cytogenetic Response) and then performed every 3 
months. Molecular response can be divided into complete 
molecular response (CMR), in which BCR-ABL transcript 
concentrations cannot be detected by RQ-PCR, and MMR 
or Major Molecular Response, in which BCR-ABL 
decreases? 3-log or the ratio of BCR-ABL/ABL is < 0.1.
Resistance	and	examination	of	mutation	detection	with	ASO	
PCR
According to National Comprehensive Cancer Network 
(NCCN) and LeukemiaNet Guidelines, resistance to tyrosine 
kinase inhibitors is defined as failure to achieve complete 
hematologic response (CHR) in 3 months, cytogenetic 
response (CR) in 6 months, or major cytogenetic response 
(MCR) in 12 months. Resistance to tyrosine kinase inhibitor 
of a drug can be divided into three, namely hematologic, 
cytogenetic and molecular resistance.
Failed therapy is defined as not achieving hematologic 
response after 3 months of therapy, or loss of complete 
hematological response at any time, or after 6 months not 
achieving cytogenetic response, or after 12 months not 
achieving major cytogenetic response, and or BCR-ABL > 
10%, or after 18 months not achieving complete cytogenetic 
response and or BCR-ABL of > 10%.1
According to Branford et al6 (2003), patients who fail 
to achieve a 1-log reduction in BCR-ABL transcripts in 
3 months or a decrease of > 2-log within 6 months, tend Figure	2. Example of electrophoresis results of BCR-ABL 
qualitative examination.8.
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not to give a significant response and at high risk for 
progressiveness. Molecular resistance is defined as the 
lack or loss of complete molecular response (BCR-ABL 
transcripts cannot be detected) using PCR RQ- or as a lack 
of major molecular remission (ie, a decrease of BCR-ABL 
transcripts > 3-log or the ratio of BCR-ABL/ABL < 0.1%, 
respectively).9
According to Corbin et	al11 (2003), certain mutations, 
such as M244V, M351T, and Phe311L also causes 
resistance to Tyrosine Kinase Inhibitors (imatinib), 
which, using biochemical and cellular tests, the mutation 
will show decreased sensitivity to imatinib respectively 
of 1, 8 and 2.8-fold. Slight shifts in terms of sensitivity 
causes kinase activity becomes sufficient to cause disease 
progression. However, in theory, the resistance caused by 
these mechanisms can be overcome with increased doses 
of imatinib.
Mutation found in T315I frequently causes of resistance 
to inhibitors of first-generation (imatinib) or second 
generation. This mutation is also associated with secondary 
imatinib resistance that usually occurs in the later stages of 
the disease and is associated with advanced age, receiving 
interferon previously, a high Sokal score, and failure to 
reach the CCR in 12 months.10
Detection of ABL kinase domain mutations is performed 
when in chronic phase the CML patients, after treatment 
with TKI drugs, provide inadequate therapeutic response 
(failure to achieve hematologic complete response in the 
first 3 months, minimal cytogenetic response within 6 
months, or a major cytogenetic response within 12 months) 
or loss of therapeutic response (defined as hematologic 
relapse, cytogenetic relapse, 1-log increase of BCR-ABL 
transcripts ratio, and the loss of major molecular response), 
or the disease becomes progressive (the occurrence of 
accelerated phase or blastic crisis).1
Mutation analysis can be done in various ways. One is 
by using Allele-Specific Olygonucleotide (ASO)-PCR. This 
method is a technique that is highly sensitive and specific 
for the detection of known mutations1. This method is even 
more sensitive than mutation detection with sequencing 
method because DNA sequencing method can only be 
useful for point mutation if the proportion of mutated cells 
is more than 30%. In cases where the number of mutated 
cells is less than 30% of total cells in the sample of the 
patients, at least 10 independent clones from patients should 
be analyzed for mutations detection, a quite expensive and 
time consuming procedure. In contrast, the ASO-PCR is 
comparatively more sensitive, specific and “economical”, 
so it is a rapid method for mutation detection.12
conclusion
The use of qualitative  multiplex PCR to detect BCR-
ABL fused gene becomes  one of the methods  to detect the 
Chronic Myelogenous Leukemia (CML). It is easier to be 
performed while the use of karryotyping was complicated 
to detect this fused genes that called philladelphia 
chromosome
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